Dr Azrif

05/08/2023

CALGB/SWOG 80702 was a trial that looked at 3 Vs 6 months chemotherapy in stage colorectal cancer. The investigators also looked at intensity and duration of physical activity after completing chemo. In summary, patients with stage 3 colorectal cancer should aim for 3 hours of brisk walking a week as it reduces the risk of cancer recurrence significantly. Time to get up and walk 😁

Among patients with stage III colon cancer enrolled in a trial of postoperative treatment, larger volumes of recreational physical activity, longer durations of light- to moderate-intensity aerobic physical activity, or any vigorous-intensity aerobic physical activity were associated with the greate...

08/06/2023

It's ok to stop immunotherapy after two years in stage 4 lung cancer.

In stage 4 lung cancer, we normally give immunotherapy for two years then stop and monitor the patient for disease relapse but there is an ongoing debate as to whether we should continue the treatment for longer than two years.

In a study published in the June 2023 JAMA Oncology journal, a group of doctors from Univ of Pennsylvania looked at patients wtih stage 4 lung cancer who continued immunotherapy beyond 2 years vs those who stopped at two years of treatment and found no significant difference in survival two years later.

Reference: JAMA Oncol. Published online June 4, 2023. doi:10.1001/jamaoncol.2023.1891

01/05/2023

Ultra- processed foods increase our risk of cancer according to a large study funded by the World Cancer Research Fund.

https://www.wcrf.org/latest/news-and-updates/ultra-processed-food-increases-cancer-rates-new-research-shows/

29/04/2023

More evidence supporting adding immunotherapy to chemotherapy before surgery for stage 2 and 3 lung cancer
The interim results of the AEGEAN clinical trial were presented two weeks ago at the American Association for Cancer Research conference.
Adding immunotherapy to chemotherapy leads to a one third reduction in the risk of cancer progression .

Patients treated with the durvalumab-based regimen before and after surgery in the AEGEAN trial had a 32% reduction in the risk of disease recurrence or progression events ORLANDO, Fla. – Patients with treatment-naïve resectable non-small cell lung cancer (NSCLC) who received neoadjuvant durvalum...

02/04/2023

Many people have incorrect ideas about cancer and its causes. This Mayo Clinic website that explains how these ideas are based on incomplete information or misinterpretation.

Get the facts and find out why these popular myths about cancer causes are wrong.

24/01/2023

Many people nowadays complain of difficulty sleeping. Here is a link to a short video with tips to improve sleep

Want to not only fall asleep quickly but also stay asleep longer? Sleep scientist Matt Walker explains how your room temperature, lighting and other easy-to-...